ABOUT THE PRODUCT
Oral brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, being developed for multiple severe autoimmune indications.
Information is owner-confirmed
Last updated 1 month ago
Price range
N/A
ABOUT THE PRODUCT
Information is owner-confirmed
Last updated 1 month ago